Monte Rosa Therapeutics, Inc.
monterosatx.comWhat Do They Do?
Develops small-molecule medicines that direct cells to destroy disease-related proteins for immune, inflammatory and cancer conditions, and discovers drug candidates for pharmaceutical partners.
10-K for FY2025, filed Mar 17, 2026We are a clinical-stage biotechnology company developing a portfolio of novel and proprietary molecular glue degraders, or MGDs. MGDs are…View ↗
We prioritize our product development to address therapeutic targets backed by strong biological and genetic rationales. We are focused on…View ↗
In October 2023, our wholly-owned subsidiary, Monte Rosa Therapeutics AG, or Monte Rosa AG, entered into a strategic collaboration and…View ↗
In September 2025, we and Novartis entered into a collaboration, option, and license agreement, under which Monte Rosa granted to Novartis…View ↗
How Do They Make Money?
Drug-company partners pay upfront for licenses and collaborations, with possible additional milestone payments and royalties tied to development and product sales. Research-collaboration revenue is earned as work progresses; distinct license revenue is earned when rights are transferred, and royalties when related sales occur.
10-K for FY2025, filed Mar 17, 2026In October 2023, our wholly-owned subsidiary, Monte Rosa Therapeutics AG, or Monte Rosa AG, entered into a strategic collaboration and…View ↗
Under the agreement, the Company received a $120.0 million non-refundable upfront payment from Novartis. The Company is entitled to receive…View ↗
The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for…View ↗
Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as…View ↗
F-12 performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure…View ↗
$123.7M
-
10-K for FY2025, filed Mar 17, 2026
$123.7M ↗
Who Are Their Customers?
Pharmaceutical partners such as Roche and Novartis work directly with Monte Rosa on drug discovery and licenses; partners take over development and commercialization of licensed programs.
10-K for FY2025, filed Mar 17, 2026In October 2023, our wholly-owned subsidiary, Monte Rosa Therapeutics AG, or Monte Rosa AG, entered into a strategic collaboration and…View ↗
In September 2025, we and Novartis entered into a collaboration, option, and license agreement, under which Monte Rosa granted to Novartis…View ↗
Under the agreement, the Company received a $120.0 million non-refundable upfront payment from Novartis. The Company is entitled to receive…View ↗
In October 2024, Monte Rosa AG and Novartis entered into a license agreement with Novartis, or the 2024 Novartis Agreement. Pursuant to the…View ↗
How Are They Changing?
Licensing programs
The company has moved from retaining worldwide rights to its pipeline to licensing selected programs to pharmaceutical partners, which take on later development and commercialization.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 17, 2026We have leveraged our QuEEN™ platform to generate our pipeline of product candidates with the potential to treat a diverse range of…View ↗
Cancer focus
The newer description centers the lead cancer program on metastatic castration-resistant prostate cancer; the earlier report covered several MYC-driven tumor types, including lung and neuroendocrine cancers.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 17, 2026Our most advanced product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1.…View ↗
MRT-2359 is an orally bioavailable MGD targeting the translation termination factor protein GSPT1 and is currently in clinical development…View ↗
Who Do They Compete With?
Competes with C4 Therapeutics, Nurix Therapeutics, Kymera Therapeutics, Bristol-Myers Squibb, Novartis, AstraZeneca, Roche, Novo Nordisk, Ventyx Biosciences, BioAge Labs, NodThera, Pfizer, Merck, BeOne Medicines, and Incyte
10-K for FY2025, filed Mar 17, 2026The main competitors in our efforts to develop targeted protein degraders or MGD therapeutics for patients include, but are not limited to…View ↗
Loading...
